The CD44 + CD24 + ESA+ phenotype has a 100-fold higher tumor-initiating capacity than non-tumorigenic cancer cells, and these cells display distinctive stem cell features, including self-renewal and the ability to generate phenotypically diverse progeny (Patil et al. 2021). This evidence concerns the gene CD44 and cancer.